(Q38211352)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24821129%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

title

Advances in the diagnosis and therapeutic management of atopic dermatitis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24821129%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

author

Christian Vestergaard

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24821129%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

author name string

Mette Deleuran

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24821129%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

language of work or name

1 reference

1 May 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24821129%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24821129%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

volume

74

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24821129%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

page(s)

757-769

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24821129%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24821129%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s40265-014-0219-3

18 March 2020

exact match

0 references

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0219-3

The infectious aspects of atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0219-3

Quality of life and childhood atopic dermatitis: the misery of living with childhood eczema

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0219-3

How atopic is atopic dermatitis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0219-3

How epidemiology has challenged 3 prevailing concepts about atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0219-3

ETFAD/EADV eczema task force 2009 position paper on diagnosis and treatment of atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0219-3

Skin diseases associated with Malassezia yeasts: facts and controversies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0219-3

Allergen- and bacterial antigen-specific T-cell clones established from atopic donors show a different profile of cytokine production

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0219-3

Regulation of caspase 14 expression in keratinocytes by inflammatory cytokines--a possible link between reduced skin barrier function and inflammation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0219-3

Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0219-3

Progressive activation of T(H)2/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0219-3

CCL27-CCR10 interactions regulate T cell-mediated skin inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0219-3

A Th2 chemokine, TARC, produced by keratinocytes may recruit CLA+CCR4+ lymphocytes into lesional atopic dermatitis skin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0219-3

Mast cells produce interleukin-25 upon Fc epsilon RI-mediated activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0219-3

Interleukin-33 in allergy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0219-3

ST2 regulates allergic airway inflammation and T-cell polarization in epicutaneously sensitized mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0219-3

IL-33 synergizes with TCR and IL-12 signaling to promote the effector function of CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0219-3

Vitamin D analogs differentially control antimicrobial peptide/"alarmin" expression in psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0219-3

Filaggrin in atopic dermatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0219-3

Filaggrin mutations are strongly associated with contact sensitization in individuals with dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0219-3

The cornified envelope: a model of cell death in the skin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0219-3

The filaggrin story: novel insights into skin-barrier function and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0219-3

Caspase-14 reveals its secrets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0219-3

The epidermal barrier function is dependent on the serine protease CAP1/Prss8

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0219-3

Loss of proteolytically processed filaggrin caused by epidermal deletion of Matriptase/MT-SP1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0219-3

Defects of filaggrin-like proteins in both lesional and nonlesional atopic skin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0219-3

Cytokine modulation of atopic dermatitis filaggrin skin expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0219-3

TNF-α downregulates filaggrin and loricrin through c-Jun N-terminal kinase: role for TNF-α antagonists to improve skin barrier.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0219-3

IL-17 downregulates filaggrin and affects keratinocyte expression of genes associated with cellular adhesion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0219-3

Placebo-controlled, double-blind, randomized, prospective study of a glycerol-based emollient on eczematous skin in atopic dermatitis: biophysical and clinical evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0219-3

Viral infections in atopic dermatitis Pathogenic aspects and clinical management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0219-3

Oat sensitization in children with atopic dermatitis: prevalence, risks and associated factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0219-3

Factors associated with the development of peanut allergy in childhood

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0219-3

Guidelines for treatment of atopic eczema (atopic dermatitis) part I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0219-3

Corticosteroids: the drugs to beat

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0219-3

The use of corticosteroids and corticosteroid phobia in atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0219-3

Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis: randomised, double blind, parallel group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0219-3

Topical steroid risk analysis: differentiating between physiologic and pathologic adrenal suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0219-3

Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0219-3

Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six-month study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0219-3

A short-term trial of tacrolimus ointment for atopic dermatitis. European Tacrolimus Multicenter Atopic Dermatitis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0219-3

Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0219-3

Two topical calcineurin inhibitors for the treatment of atopic dermatitis in pediatric patients: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0219-3

Treatment of Staphylococcus aureus colonization in atopic dermatitis decreases disease severity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0219-3

Staphylococcus aureus colonization in atopic dermatitis and its therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0219-3

Antibiotic treatment of cutaneous infections with Staphylococcus aureus in patients with atopic dermatitis: current antimicrobial resistances and susceptibilities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0219-3

Dilute bleach baths for Staphylococcus aureus colonization in atopic dermatitis to decrease disease severity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0219-3

Narrow band UVB: is it effective and safe for paediatric psoriasis and atopic dermatitis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0219-3

Prednisolone vs. ciclosporin for severe adult eczema. An investigator-initiated double-blind placebo-controlled multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0219-3

Efficacy and safety of systemic treatments for moderate-to-severe atopic dermatitis: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0219-3

Leukocyte adhesion: a suitable target for anti-inflammatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0219-3

Low-dose methotrexate treatment for moderate-to-severe atopic dermatitis in adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0219-3

An open-label, dose-ranging study of methotrexate for moderate-to-severe adult atopic eczema.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0219-3

A randomized trial of methotrexate versus azathioprine for severe atopic eczema.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0219-3

Methotrexate versus cyclosporine in the treatment of severe atopic dermatitis in children: a multicenter experience from Egypt

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0219-3

Dermatologic uses of methotrexate in children: indications and guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0219-3

Azathioprine in severe adult atopic dermatitis: a double-blind, placebo-controlled, crossover trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0219-3

Azathioprine dosed by thiopurine methyltransferase activity for moderate-to-severe atopic eczema: a double-blind, randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0219-3

A retrospective evaluation of azathioprine in severe childhood atopic eczema, using thiopurine methyltransferase levels to exclude patients at high risk of myelosuppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0219-3

Severe adult atopic dermatitis: treatment with mycophenolate mofetil in 8 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0219-3

First experience with enteric-coated mycophenolate sodium (Myfortic) in severe recalcitrant adult atopic dermatitis: an open label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0219-3

Recombinant interferon gamma therapy for atopic dermatitis

21 January 2018

2 references

https://api.crossref.org/works/10.1007%2FS40265-014-0219-3

21 January 2018

12 December 2020

Long-term therapy with recombinant interferon-gamma (rIFN-gamma) for atopic dermatitis

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0219-3

Long-term effectiveness and safety of recombinant human interferon gamma therapy for atopic dermatitis despite unchanged serum IgE levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0219-3

Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0219-3

Efficacy of omalizumab in the treatment of atopic dermatitis: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0219-3

A randomized controlled evaluator-blinded trial of intravenous immunoglobulin in adults with severe atopic dermatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0219-3

Long-term Efficacy of Intravenous Immunoglobulin Therapy for Moderate to Severe Childhood Atopic Dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0219-3

Food allergy and food sensitization in early childhood: results from the DARC cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0219-3

The evaluation and management of food allergy in atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0219-3

Effect of nutrient supplementation on atopic dermatitis in children: a systematic review of probiotics, prebiotics, formula, and fatty acids

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0219-3

Relationship between itch and psychological status of patients with atopic dermatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0219-3

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0219-3

Therapeutic patient education in children with atopic dermatitis: position paper on objectives and recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0219-3

Therapeutic patient education in atopic dermatitis: worldwide experiences.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0219-3

Guidelines for treatment of atopic eczema (atopic dermatitis) Part II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0219-3

The European TREatment of severe Atopic eczema in children Taskforce (TREAT) survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0219-3

Hanifin's and Rajka's minor criteria for atopic dermatitis: Which do 2-year-olds exhibit?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0219-3

Reviewing the evidence for mycophenolate mofetil as a new teratogen: Case report and review of the literature

21 January 2018

1 reference

12 December 2020

The treatment of severe atopic dermatitis in childhood with narrowband ultraviolet B phototherapy

1 reference

12 December 2020

IL-31 regulates differentiation and filaggrin expression in human organotypic skin models

1 reference

12 December 2020

Atopic dermatitis may be linked to whether a child is first- or second-born and/or the age of the mother

1 reference

12 December 2020

Subcutaneous immunotherapy with a depigmented polymerized birch pollen extract--a new therapeutic option for patients with atopic dermatitis

1 reference

12 December 2020

High doses intravenous immunoglobulin versus oral cyclosporine in the treatment of severe atopic dermatitis

1 reference

12 December 2020

Enteric-coated mycophenolate sodium versus cyclosporin A as long-term treatment in adult patients with severe atopic dermatitis: a randomized controlled trial

1 reference

12 December 2020

Efficacy and safety of long-term treatment with cyclosporin A for atopic dermatitis

1 reference

12 December 2020

Interleukin-22 downregulates filaggrin expression and affects expression of profilaggrin processing enzymes

1 reference

12 December 2020

Anti-CD20 (rituximab) treatment improves atopic eczema

1 reference

12 December 2020

1 reference

12 December 2020

Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis

1 reference

12 December 2020

Prenatal exposure to mycophenolate mofetil: an updated estimate.

1 reference

12 December 2020

Development of atopic dermatitis-like skin lesions in STAT6-deficient NC/Nga mice

1 reference

12 December 2020

Systematic review of treatments for atopic eczema.

1 reference

12 December 2020

Usefulness of specific immunotherapy in patients with atopic dermatitis and allergic sensitization to house dust mites: a multi-centre, randomized, dose-response study

1 reference

12 December 2020

Photo(chemo)therapy in the management of atopic dermatitis: an updated systematic review with implications for practice and research

1 reference

12 December 2020

Mycophenolate mofetil therapy for moderate to severe atopic dermatitis

1 reference

12 December 2020

Psychophysiological effects of stress management in patients with atopic dermatitis: a randomized controlled trial.

1 reference

12 December 2020

Improvement of treatment-refractory atopic dermatitis by immunoadsorption: a pilot study

1 reference

12 December 2020

Efficacy of anti-IgE therapy in patients with atopic dermatitis

1 reference

12 December 2020

Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. The European Tacrolimus Ointment Study Group

1 reference

12 December 2020

Anti-CD20 (rituximab) treatment for atopic eczema

1 reference

12 December 2020

IL-22-producing "T22" T cells account for upregulated IL-22 in atopic dermatitis despite reduced IL-17-producing TH17 T cells

1 reference

12 December 2020

Staphylococcus aureus in the lesions of atopic dermatitis

1 reference

12 December 2020

Oral evening primrose oil and borage oil for eczema

1 reference

12 December 2020

Gene expression is differently affected by pimecrolimus and betamethasone in lesional skin of atopic dermatitis

1 reference

12 December 2020

Methotrexate for the treatment of adult atopic dermatitis

1 reference

12 December 2020

Omalizumab therapy in atopic dermatitis: depletion of IgE does not improve the clinical course - a randomized, placebo-controlled and double blind pilot study

1 reference

12 December 2020

Therapy of severe atopic dermatitis in adults

1 reference

12 December 2020

Hypothalamus-pituitary-adrenal axis suppression by superpotent topical steroids

1 reference

12 December 2020

Use of methotrexate in young patients with respect to the reproductive system

1 reference

12 December 2020

Characterization of protease processing sites during conversion of rat profilaggrin to filaggrin

1 reference

12 December 2020

Narrowband ultraviolet B phototherapy in children with moderate-to-severe eczema: a comparative cohort study

1 reference

12 December 2020

Anti-interleukin-31-antibodies ameliorate scratching behaviour in NC/Nga mice: a model of atopic dermatitis

1 reference

12 December 2020

Effectiveness of the ascomycin macrolactam SDZ ASM 981 in the topical treatment of atopic dermatitis

1 reference

12 December 2020

The atopic eczema/dermatitis syndrome. Epidemiology, natural course, and immunology of the IgE-associated ("extrinsic") and the nonallergic ("intrinsic") AEDS.

1 reference

12 December 2020

Role of illness representations and coping in patients with atopic dermatitis: a cross-sectional study

1 reference

12 December 2020

Interventions to reduce Staphylococcus aureus in the management of atopic eczema

1 reference

12 December 2020

Differential in situ expression of IL-17 in skin diseases.

1 reference

12 December 2020

Probiotics in the treatment and prevention of atopic dermatitis

1 reference

12 December 2020

Fleshing out filaggrin phenotypes

1 reference

12 December 2020

IL-25 in atopic dermatitis: a possible link between inflammation and skin barrier dysfunction?

1 reference

12 December 2020

Success of omalizumab as monotherapy in adult atopic dermatitis: case report and discussion of the high-affinity immunoglobulin E receptor, FcepsilonRI.

1 reference

12 December 2020

Analysis of the cytokine pattern expressed in situ in inhalant allergen patch test reactions of atopic dermatitis patients

1 reference

12 December 2020

10.1007/S40265-014-0219-3

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24821129%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

18 March 2020

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24821129%20AND%20SRC:MED&resulttype=core&format=json